Business
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025 – – Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget – – Common warts affec
About this update from Verrica Pharmaceuticals Inc.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/35B6rwmMy25cs4KMlGMlxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule –","length":129,"tagName":"p"},{"type":"text","content":"– Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025 –","length":202,"tagName":"p"},{"type":"text","content":"– Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget – ","length":146,"tagName":"p"},{"type":"text","content":"– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for this multi-billion dollar addressable market –","length":188,"tagName":"p"},{"type":"text","content":"– Company expects to dose first patient in the Phase 3 trial in the United States in the fourth quarter of 2025 –","length":113,"tagName":"p"},{"type":"text","content":"– Verrica to maintain ownership of global rights to YCANTH for all indications in all territories outside of Japan –","length":116,"tagName":"p"},{"type":"text","content":"WEST CHESTER, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it has entered into the second amendment to its existing Collaboration and Licensing Agreement with Torii Pharmaceutical Co. Ltd. (“Torii”) to initiate a global pivotal Phase 3 clinical trial of Verrica’s product, YCANTH®, for the treatment of common warts.","length":509,"tagName":"p"},{"type":"text","content":"“We are extremely excited ...